Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208985 · ClinicalTrials.gov registry record · Phase 3
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
A Phase 3 study, sponsored by HRA Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,270
- Enrollment target
NCT03208985 is a Phase 3 study that has completed, run by HRA Pharma. The registered enrollment target is 1,270 participants.
The verdict
NCT03208985, a Phase 3 study, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,270 participants
- Enrollment target
Study Summary
This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.
Interventions
- DRUG Use Phase (Ulipristal Acetate, 30 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,270 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2018-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03208985
The ClinicalTrials.gov registry entry for NCT03208985 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HRA Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Use Phase (Ulipristal Acetate, 30 mg) is the first listed.
NCT03208985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03208985 about?
NCT03208985 is a clinical study titled "A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions". This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.
What is the current status of trial NCT03208985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,270 participants. The study started on 2017-05-23. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT03208985?
The interventions under investigation include: Use Phase (Ulipristal Acetate, 30 mg) (DRUG).
Who is sponsoring clinical trial NCT03208985?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.